Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Inclusion Criteria

• •(PRE-OPERATIVE \[OP\])
• •Patients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgery
• •Borderline ovarian cancer with ascites
• •Eastern Cooperative Oncology Group (ECOG)/Zubrod/ Southwest Oncology Group (SWOG) performance status \< 2 (Karnofsky performance status \>= 70%)
• •Ability to provide informed consent
• •Absolute neutrophil count \> 1000/uL
• •Platelet count \> 100'000/uL
• •Serum creatinine =\< 1.5 x upper limit of normal (ULN)
• •Bilirubin =\< 1.5 x normal
• •Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) levels =\< 2 x ULN
• •No known bleeding disorders
• •No known sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)
• •No active peptic ulcer disease
• •No active bleeding
• •SECONDARY ELIGIBILITY
• •Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer on frozen section diagnosis
• •Placement of an intraperitoneal port at the time of surgery for anticipated use for adjuvant chemotherapy or management of post-operative ascites
• •If epidural catheter was used - the catheter must be removed prior to treatment
• •No active bleeding